Current Cancer Drug Targets

Editor-in-Chief:

Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
USA

Back

Become EABM
Become Reviewer

Most Accessed Articles

Ponatinib: A Review of Efficacy and Safety

Volume: 18   Issue: 9
Pp: 847-856
Fulvio Massaro, Matteo Molica and Massimo Breccia*
DOI: 10.2174/1568009617666171002142659

Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update

Volume: 18   Issue: 9
Pp: 857-868
Shirin Eyvazi, Safar Farajnia*, Siavoush Dastmalchi, Farzad Kanipour, Habib Zarredar and Mojghan Bandehpour
DOI: 10.2174/1568009618666180102102311

p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents

Volume: 18   Issue: 8
Pp: 749-772
Surendra Kumar Nayak*, Gopal L. Khatik, Rakesh Narang, Vikramdeep Monga and Harish Kumar Chopra
DOI: 10.2174/1568009617666170623111953

Parp Inhibitors for the Treatment of Ovarian Cancer

Volume: 18   Issue: 9
Pp: 877-893
Laura Cortesi, Angela Toss* and Iole Cucinotto
DOI: 10.2174/1568009618666180308104646

Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety

Volume: 15   Issue: 6
Pp: 452-462
Saїd C. Azoury, David M. Straughan and Vivek Shukla
DOI: 10.2174/156800961506150805145120

Understanding Cancer Drug Resistance by Developing and Studying Resistant Cell Line Models

Volume: 16   Issue: 3
Pp: 226-237
Cristina P.R. Xavier, Milica Pesic and M. Helena Vasconcelos
DOI: 10.2174/1568009616666151113120705

Role of MicroRNAs in Treatment Response in Prostate Cancer open access plus

Volume: 18   Issue: 10
Pp: 929-944
Anshuli Razdan, Paul de Souza* and Tara Laurine Roberts
DOI: 10.2174/1568009618666180315160125